VC-backed Metacrine goes public
San Diego-based Metacrine, a developer of therapies for patients with liver, gastrointestinal and metabolic diseases, has raised about $85 million for its IPO after pricing its 6.54 million shares at $13 per share.
San Diego-based Metacrine, a developer of therapies for patients with liver, gastrointestinal and metabolic diseases, has raised about $85 million for its IPO after pricing its 6.54 million shares at $13 per share.
Copyright PEI Media
Not for publication, email or dissemination